Abstract

Induction of a functional CD8(+) T-cell response is the important criterion for cancer vaccines, and it is unclear whether acute or chronic live vectors are better suited for cancer antigen delivery. We have evaluated the tumor protective ability of two recombinant vectors, Listeria monocytogenes (LM) and Salmonella typhimurium (ST), both expressing ovalbumin (OVA). Although both vectors induced a similar OVA-specific CD8(+) T-cell response in the long term, LM-OVA induced mainly central-phenotype (T(CM), CD44(high)CD62L(high)), whereas ST-OVA induced mainly effector-phenotype (T(EM), CD44(high)CD62L(low)) cells. Both vectors induced functional OVA-specific CD8(+) T cells that expressed IFN-gamma and killed targets specifically in vivo. However, only LM-OVA-vaccinated mice were protected against B16-OVA tumors. This correlated to the ability of CD8(+) T cells generated against LM-OVA, but not against ST-OVA, to produce interleukin 2 and exhibit profound homeostatic and antigen-induced proliferation in vivo. Furthermore, adoptive transfer of memory CD8(+) T cells generated against LM-OVA (but not against ST-OVA) into recipient mice resulted in their trafficking to tumor-draining lymph nodes conferring protection. Although cytotoxicity and IFN-gamma production are considered to be the principal functions of memory CD8(+) T cells, the vaccine delivery strategy may also influence memory CD8(+) T-cell quality, and ability to proliferate and traffic to tumors. Thus, for efficacy, cancer vaccines should be selected for their ability to induce self-renewing memory CD8(+) T cells (CD44(high)IL-7Ralpha(high)CD62L(high)) besides their effector functions.

Highlights

  • A major goal of cancer immunotherapy is to generate long-lived CD8+ T cells for efficacious protection

  • Listeria monocytogenes (LM)-OVA induces a better tumor protection compared with Salmonella typhimurium (ST)-OVA

  • We show that the phenotype of CD8+ T-cell response to the same antigen may be differentially skewed by immunization strategy

Read more

Summary

Introduction

A major goal of cancer immunotherapy is to generate long-lived CD8+ T cells for efficacious protection. Despite the success in generating CD8+ T-cell responses to self antigens [1,2,3,4,5,6], cancer immunotherapy has provided objective long-term remission in only a small proportion of patients with select cancer types [7]. Memory CD8+ T cells are heterogeneous in phenotype: effectormemory (TEM) and central-memory (TCM) cells [9,10,11]. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). TCM are considered to be more potent at mediating protection against pathogens [13, 15,16,17]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.